rectal cancer bevacizumab telangiectasia radiotherapy
Conditions
Interventions
2 sigmoidoscopies for mucosal biopsy sampling.
Sponsors
NKI-AVL (Netherlands ancer Institute)
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients, diagnosed with local tumor residue / recurrence or metastasis, 6 months or longer after the start of their initial pre-operative radiotherapy or chemo-radio therapy (CRT) and will now be treated with bevacizumab; 2. Rectal endoscopy is possible; 3. Aged over 18 years; 4. Written informed consent is provided.
Exclusion criteria
Exclusion criteria: 1. Previous abdomino-perineal resection (APR) (no endoscopic access); 2. Anastomotic bleeding, leakage or breakdown at study enrolment; 3. Use of anticoagulants or anti aggregants.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary end-point of this study will be the number and size of teleangiectasia encountered, lymph vessel morphology and immunohistochemical evaluation of inflammation and vessel maturation. | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary endpoint will be the number of complications following bevacizumab treatment and or endoscopic procedures: Rates of anastomotic leakage or breakdown, rectal ulcer or bleeding. | — |
Contacts
Public ContactS. Vanhoutvin
Netherlands Cancer Institute Dept of Biometrics
Outcome results
None listed